No data pointing to CYP-metabolism. The drug has, however, been shown to interfere with hepatic CYPs in animal studies. Probably of small human clinical significance.

(To be edited, initial data ST OCT 04) Monocyclic betalactam antibiotic parenterally administered (1-2 g x 3). Used in various gramnegative bacterial infections, e.g. Pneumonia, urinary tract infections, urogenital gonococc infections, upper respiratory tract infections in cystic fibrosis. About 60.-80% ot the dose is excreted in unchanged form in urine within 8 hours. In male rats the total hepatic CYP content is reported to decrease after administration of aztreonam. In female rats the hepatic CYP-activity is slightly increased: Ohmori et al. Aztreonam decreases hepatic … (PMID 8153141). Sagami et al. Effect of aztreonam on immuno... (PMID 2813957). Horie et al. Sex difference in responsiveness... (PMID 3566801)